

## Bosutinib Monotherapy

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.	C92	00224a	CDS

*\*If the reimbursement status is not defined<sup>1</sup>, the indication has yet to be assessed through the formal HSE reimbursement process.*

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Bosutinib is taken orally once daily until disease progression or unacceptable toxicity develops.

Drug	Dose	Route	Cycle
Bosutinib	500mg daily	PO once daily with food.	Continuous
Missed doses should not be replaced. Normal dosing should be resumed at the next scheduled dose. If a patient vomits within a few hours of taking the drug do not repeat the dose			

### ELIGIBILITY:

- Indications as above
- ECOG 0-2

### EXCLUSIONS:

- Hypersensitivity to bosutinib or any of the excipients
- Hepatic impairment
- Serum creatinine > 1.5xULN
- Pregnancy
- Breastfeeding

### USE WITH CAUTION:

Use with caution in patients with

- Uncontrolled or significant cardiac disease (e.g. recent MI, CHF or unstable angina)
- Recent or ongoing clinically significant gastrointestinal disorder

### PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies.

### TESTS:

#### Baseline tests:

NCCP Regimen: Bosutinib Monotherapy	Published: 20/12/2013 Review: 21/05/2020	Version number: 3
Tumour Group: Leukaemia/BMT NCCP Regimen Code: 00224	IHS Contributor: Dr Eibhlin Conneally	Page 1 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

- FBC, renal and liver profile
  - ECG
  - Bone marrow examination for cytogenetic analysis.
  - Analysis by RQ-PCR BCR-ABL transcript level and screening for BCR-ABL kinase–domain mutation
  - Hepatitis B virus (HBV) screening required before initiating treatment with BCR-ABL tyrosine kinase inhibitors (TKIs)
- \* (See Adverse Effects /Regimen Specific Complications for further information)

**Regular tests:**

- FBC, renal and liver profile weekly for the first month and then monthly thereafter or as clinically indicated.
- ECG should be repeated 7 days after start of treatment and as clinically indicated, including 7 days after dose changes.
- BCR-ABL transcript analysis every 3 months

**Disease monitoring:**

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

**DOSE MODIFICATIONS:**

- Any dose modification should be discussed with a Consultant.
- Consider dose escalation to 600mg once daily with food in patients who do not achieve complete haematologic response (CHR) by week 8 or complete cytogenetic response (CCyR) by week 12 and who do not have grade ≥ 3 adverse reactions.
- Doses > 600mg/day have not been studied and therefore should not be given.

**Haematological:**

**Table 1: Dose modification of bosutinib in haematological toxicity**

ANC <sup>9</sup> (x10 <sup>9</sup> /L)		Platelets <sup>9</sup> (x10 <sup>9</sup> /L)	Dose
<1	and/or	<50	Hold bosutinib until ANC ≥ 1x10 <sup>9</sup> /L and platelets ≥ 50x10 <sup>9</sup> /L. Resume treatment with bosutinib at the same dose if recovery occurs within 2 weeks. If blood counts remain low for > 2 weeks, reduce dose by 100 mg and resume treatment. If cytopenia recurs, reduce dose by 100 mg upon recovery and resume treatment. Doses < 300 mg/day have not been evaluated.

NCCP Regimen: Bosutinib Monotherapy	Published: 20/12/2013 Review: 21/05/2020	Version number: 3
Tumour Group:Leukaemia/BMT NCCP Regimen Code: 00224	IHS Contributor: Dr Eibhlin Conneally	Page 2 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

**Renal and Hepatic Impairment:**

**Table 2: Dose modification of bosutinib in renal impairment**

Renal Impairment	
Cr Cl (ml/min)	Dose
30-50	400mg daily
<30	300mg daily
Dose escalation to 500 mg once daily for patients with moderate renal impairment or to 400 mg once daily in patients with severe renal impairment may be considered in those who did not experience severe or persistent moderate adverse reactions, under any of the following circumstances. Circumstances for dose escalation - Failure to achieve complete haematologic response (CHR) by week 8 - Failure to achieve complete cytogenetic response (CCyR) by week 12	

**Table 3: Dose adjustments for hepatic impairment**

Transaminase (AST, ALT)		Bilirubin		AP	Dose Modification
>5xULN					Interrupt bosutinib therapy until recovery to ≤ 2.5 x ULN. Therapy may be resumed at 400 mg once daily thereafter. If recovery takes longer than 4 weeks, discontinuation of bosutinib should be considered.
≥3xULN	and	> 2xULN	and	< 2xULN	Discontinue bosutinib.

**Management of adverse events:**

**Table 4: Dose Modification of bosutinib for Adverse Events**

Adverse reactions	Recommended dose modification / discontinuation
Non-Haematologic Clinically significant grade 2 or ≥ Grade 3	Bosutinib therapy should be interrupted and may be resumed at 400mg once daily once the toxicity has resolved. If clinically appropriate, re-escalation of the dose to 500mg once daily should be considered.
Grade ≥3 Diarrhoea	Therapy should be interrupted and may be resumed at 400 mg once daily upon recovery to grade ≤1.
Lipase elevation accompanied by abdominal symptoms	Bosutinib treatment must be interrupted and appropriate diagnostic measures considered to exclude pancreatitis.

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:** Minimal-Low (Refer to local policy).

**PREMEDICATIONS:** Not usually required

**OTHER SUPPORTIVE CARE:**

Medication may be required (particularly on initiating Bosutinib) for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.

NCCP Regimen: Bosutinib Monotherapy	Published: 20/12/2013 Review: 21/05/2020	Version number: 3
Tumour Group: Leukaemia/BMT NCCP Regimen Code: 00224	IHS Contributor: Dr Eibhlin Conneally	Page 3 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

**This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.**

- **Diarrhoea and vomiting:** Patients with diarrhoea and vomiting should be managed using standard-of-care treatment. In addition, these events can also be managed by withholding bosutinib temporarily, dose reduction, and/or discontinuation of bosutinib. The antiemetic agent, domperidone, should be avoided. It should only be used, if other medicinal products are not efficacious. In these situations an individual benefit-risk assessment is mandatory and patients should be monitored for occurrence of QT prolongation.
- **Fluid retention:** Treatment with bosutinib may be associated with fluid retention including pericardial effusion, pleural effusion and pulmonary oedema. Patients should be monitored and managed using standard-of-care treatment. In addition, these events can also be managed by withholding bosutinib temporarily, dose reduction, and/or discontinuation of bosutinib.
- **Infections:** Bosutinib may predispose patients to bacterial, fungal, viral or protozoan infections.
- **Proarrhythmic potential:** Bosutinib should be administered with caution to patients who have a history of or predisposition for QTc prolongation, who have uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia, or who are taking medicinal products that are known to prolong the QT interval (e.g. anti-arrhythmic medicinal products and other substances that may prolong QT).
- **HBV:** Cases of reactivation of HBV have occurred in patients who are chronic carriers of HBV after they received BCR-ABL TKIs. Some cases of HBV reactivation resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome. Experts in liver disease and the treatment of HBV should be consulted before treatment in patients with positive HBV serology (including those with active disease) is initiated and for patients who test positive for HBV infection during treatment. Patients who are carriers of HBV and require treatment with BCR-ABL TKIs should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.

## DRUG INTERACTIONS:

- The concomitant use of bosutinib with strong or moderate CYP3A inhibitors should be avoided, as an increase in bosutinib plasma concentration will occur. Selection of an alternate concomitant medicinal product with no or minimal CYP3A inhibition potential, if possible, is recommended. If a strong or moderate CYP3A inhibitor must be administered during bosutinib treatment, an interruption of bosutinib therapy or a dose reduction in bosutinib should be considered.
- Grapefruit products, including grapefruit juice and other foods that are known to inhibit CYP3A should be avoided.
- The concomitant use of bosutinib with strong or moderate CYP3A inducers should be avoided as a decrease in bosutinib plasma concentration will occur
- Proton pump inhibitors may decrease bosutinib drug levels. Short-acting antacids should be considered as an alternative to PPIs and administration times of bosutinib and antacids should be separated (i.e. take bosutinib in the morning and antacids in the evening) whenever possible.
- Bosutinib should be used with caution in patients who have or may develop prolongation of QT, including those patients taking anti-arrhythmic medicinal products or other medicinal products that may lead to QT prolongation.
- Current drug interaction databases should be consulted for more information.

NCCP Regimen: Bosutinib Monotherapy	Published: 20/12/2013 Review: 21/05/2020	Version number: 3
Tumour Group:Leukaemia/BMT NCCP Regimen Code: 00224	IHS Contributor: Dr Eibhlin Conneally	Page 4 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## ATC CODE:

Bosutinib - L01XE14

## REFERENCES:

1. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. *Blood*. 2011;118(17):4567–4576.
2. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. *J Clin Oncol*. 2012;30(28):3486–3492.
3. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood*. 2012;119(15):3403–3412.
4. BCR-ABL tyrosine inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) - Important Safety Information from Novartis, Pfizer, BMS and Ariad as approved by the HPRA Available at [http://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---bcr-abl-tyrosine-kinase-inhibitors-\(imatinib-dasatinib-nilotinib-bosutinib-ponatinib\).pdf?sfvrsn=0](http://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---bcr-abl-tyrosine-kinase-inhibitors-(imatinib-dasatinib-nilotinib-bosutinib-ponatinib).pdf?sfvrsn=0)
5. BOSULIF® Summary of Product Characteristics Accessed April 2018. Available at [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/002373/WC500141721.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002373/WC500141721.pdf)

Version	Date	Amendment	Approved By
1	20/12/2013		Dr Eibhlin Conneally
2	03/05/2016	Updated dose modifications in renal impairment, drug interactions and inclusion of recommendations relating to testing for HBV and treatment of patients with HBV and BCR-ABL TKIs	Dr Eibhlin Conneally
3	21/05/2018	Updated with new NCCP regimen template	Dr Eibhlin Conneally

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

<sup>i</sup> ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

NCCP Regimen: Bosutinib Monotherapy	Published: 20/12/2013 Review: 21/05/2020	Version number: 3
Tumour Group: Leukaemia/BMT NCCP Regimen Code: 00224	IHS Contributor: Dr Eibhlin Conneally	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		